Association Between Disease Severity and Clinical, Histopathological, and Eosinophilic Markers in Patients With Bullous Pemphigoid (BP-EPIC) (BP-EPIC)
Correlation of Disease Severity With Histopathological Features, Serum IgE Levels, Eosinophil Count, and Tissue Expression of Eosinophilic Cationic Protein and Periostin in Patients With Bullous Pemphigoid
Bullous pemphigoid is an autoimmune subepidermal blistering disease characterized by eosinophilic inflammation and variable disease severity. This retrospective observational study aims to evaluate the relationship between disease severity and histopathological features, serum IgE levels, peripheral eosinophil counts, and the expression of eosinophilic cationic protein (ECP) and periostin in skin biopsy specimens of patients with bullous pemphigoid.
Immunohistochemical staining for ECP and periostin will be assessed semi-quantitatively and correlated with clinical and laboratory parameters, including BPDAI scores, eosinophil counts, serum IgE levels, hospitalization history, and disease relapse. The study seeks to identify potential tissue biomarkers associated with disease activity and severity in bullous pemphigoid.
Přehled studie
Postavení
Podmínky
Detailní popis
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease and is characterized by autoantibodies directed against hemidesmosomal proteins. Eosinophils and eosinophil-associated mediators are believed to play a central role in disease pathogenesis. Periostin and eosinophilic cationic protein (ECP) have been implicated in eosinophilic inflammation; however, their relationship with clinical disease severity in BP remains incompletely understood.
This single-center retrospective observational study will include patients diagnosed with bullous pemphigoid at the University of Health Sciences, Istanbul Training and Research Hospital. Clinical, laboratory, and histopathological data will be collected from medical records.
The study will evaluate demographic characteristics, disease severity measured by BPDAI, serum IgE levels, peripheral eosinophil counts, hospitalization history, relapse frequency, and other clinicopathological parameters. Archived skin biopsy specimens will undergo immunohistochemical staining for periostin and ECP. Staining intensity will be assessed using semi-quantitative scoring methods and correlated with clinical and laboratory findings.
The primary objective is to determine whether periostin and ECP expression levels are associated with disease severity. Secondary objectives include evaluating correlations between tissue biomarker expression and serum IgE levels, eosinophil counts, hospitalization, and disease recurrence.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní místa
-
-
FATİH
-
Istanbul, FATİH, Turecko (Türkiye), 34096
- S.B.Ü. İstanbul Eğitim ve Araştırma Hastanesi
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Age ≥18 years.
- Diagnosis of bullous pemphigoid confirmed by compatible clinical, histopathological, and/or direct immunofluorescence findings.
- Availability of archived skin biopsy specimens suitable for immunohistochemical evaluation of periostin and eosinophilic cationic protein (ECP).
- Availability of clinical and laboratory data, including BPDAI score, serum IgE level, and peripheral eosinophil count.
Exclusion Criteria:
- Age <18 years.
- Diagnosis other than bullous pemphigoid.
- Inadequate or unavailable biopsy specimens for immunohistochemical analysis.
- Missing clinical, histopathological, or laboratory data required for study analyses.
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
|---|
|
Bullous Pemphigoid Patients
Patients with bullous pemphigoid included in a retrospective observational study evaluating the relationship between disease severity and periostin and ECP expression in skin biopsy specimens.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Correlation Between BPDAI Score and Periostin Immunohistochemical Expression
Časové okno: Baseline (retrospective assessment of existing clinical and histopathological data)
|
Correlation between BPDAI disease activity score and periostin immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens from patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical and histopathological data)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Correlation Between Periostin Immunohistochemical Expression and Serum Total IgE Levels
Časové okno: Baseline (retrospective assessment of existing clinical, laboratory, and histopathological data
|
Correlation between periostin immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and serum total IgE levels (IU/mL) in patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical, laboratory, and histopathological data
|
|
Correlation Between Eosinophilic Cationic Protein Immunohistochemical Expression and Peripheral Blood Eosinophil Count
Časové okno: Baseline (retrospective assessment of existing clinical, laboratory, and histopathological data)
|
Correlation between eosinophilic cationic protein (ECP) immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and peripheral blood eosinophil count (cells/µL) in patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical, laboratory, and histopathological data)
|
|
Correlation Between Periostin Expression and Disease Relapse Frequency
Časové okno: Baseline (retrospective assessment of existing clinical and histopathological data
|
Correlation between periostin immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and disease relapse frequency (number of relapses) in patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical and histopathological data
|
|
Correlation Between Periostin Immunohistochemical Expression and Hospitalization History
Časové okno: Baseline (retrospective assessment of existing clinical and histopathological data)
|
Correlation between periostin immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and hospitalization history (yes/no) in patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical and histopathological data)
|
|
Correlation Between Eosinophilic Cationic Protein Expression and Disease Relapse Frequency
Časové okno: Baseline (retrospective assessment of existing clinical and histopathological data)
|
Correlation between eosinophilic cationic protein (ECP) immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and disease relapse frequency (number of relapses) in patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical and histopathological data)
|
|
Correlation Between Eosinophilic Cationic Protein Immunohistochemical Expression and Hospitalization History
Časové okno: Baseline (retrospective assessment of existing clinical and histopathological data)
|
Correlation between eosinophilic cationic protein (ECP) immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and hospitalization history (yes/no) in patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical and histopathological data)
|
|
Correlation Between BPDAI Score and Eosinophilic Cationic Protein Expression
Časové okno: Baseline (retrospective assessment of existing clinical, laboratory, and histopathological data)
|
Correlation between BPDAI disease activity score and tissue eosinophilic cationic protein (ECP) expression assessed by immunohistochemistry using a semiquantitative 0-3 staining score in skin biopsy specimens from patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical, laboratory, and histopathological data)
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Studijní židle: Ayse Esra Koku Aksu, Prof.Dr., University of Health Sciences, Istanbul Training and Research Hospital
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- SBU-IEAH-KAEK-20262404-26
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Bulózní pemfigoid (BP)
-
University of DelawareDokončenoZdravé sedavé dospělé s BPSpojené státy
-
Chengdu Kangnuoxing Biopharma,Inc.Zatím nenabírámeBulózní pemfigoid (BP)Čína
-
University Hospital, RouenDokončenoBulózní pemfigoid (BP)Francie
-
AKARI TherapeuticsDokončenoBulózní pemfigoid (BP)Německo, Holandsko
-
Bioverativ, a Sanofi companyAssign Data Management and Biostatistics GmbH; Quest Diagnostics-Nichols Insitute a další spolupracovníciDokončenoEnd-stage Renal Disease (ESRD) | Studené aglutininové onemocnění (CAD) | Bulózní pemfigoid (BP) | Teplá autoimunitní hemolytická anémie (WAIHA)Rakousko
-
Erimos PharmaceuticalsUkončenoChronická lymfocytární leukémie (CLL) | Akutní myeloidní leukémie (AML) | Chronická myelomonocytární leukémie (CMML) | Myelodysplastický syndrom (MDS) | Akutní lymfocytární leukémie (ALL) | Leukémie | Dospělá T-buněčná leukémie (ATL) | Chronická myeloidní leukémie (CML-BP)Spojené státy
-
Chugai PharmaceuticalZápis na pozvánkuAntifosfolipidový syndrom (APS) | Imunitní trombocytopenie (ITP) | Dermatomyozitida (DM) | Bulózní pemfigoid (BP) | Behçetův syndrom (BS) | Imunitně zprostředkovaná nekrotizující myopatie (IMNM)Maďarsko, Austrálie, Japonsko, Německo, Tchaj-wan, Rakousko, Bulharsko, Chorvatsko, Francie, Itálie, Holandsko, Norsko, Portugalsko, Rumunsko, Kanada, Španělsko, Česko, Polsko, Turecko (Türkiye)
-
Chugai PharmaceuticalNáborAntifosfolipidový syndrom (APS) | Imunitní trombocytopenie (ITP) | Dermatomyozitida (DM) | Bulózní pemfigoid (BP) | Behçetův syndrom (BS) | Imunitně zprostředkovaná nekrotizující myopatie (IMNM)Japonsko, Spojené státy, Austrálie, Kanada, Maďarsko, Tchaj-wan, Rakousko, Bulharsko, Chorvatsko, Francie, Německo, Itálie, Holandsko, Norsko, Portugalsko, Rumunsko, Česko, Polsko, Španělsko, Turecko (Türkiye)